and prostaglandin (50 µg). While the penis was erect, a protractor was used to measure the baseline angle of penile curvature. Curvature was measured on the concave side of the penile shaft, with the angle of curvature used as a fulcrum; essentially, the middle of the protractor was placed over the angle of curvature. Doppler ultrasonography was used to measure peak systolic velocity (PSV) and end-diastolic velocity (EDV). Stretched penile length and penile girth were also measured at this visit.
At a second visit 1 to 3 weeks after the initial (baseline) visit, the patients received PM-MSCs, which were injected intracavernosally. First, 1 mL of PM-MSCs was diluted with 2 mL of isotonic saline solution, to a total of 3 mL. Up to 2 mL of the diluted PM-MSC solution was then injected in and around the Peyronie plaques. The rest of the PM-MSC solution was then injected evenly into both corpora at the base at the base of the penis.
No patient received additional PM-MSC injections after this visit during the course of the study. In the current study, we assessed the use of placental matrix-derived mesenchymal stem cells (PM-MSCs) to manage PD in humans.
Methods
The present prospective study took place from August 2013 to March 2015 at a private practice urology clinic. The study was approved by the Western Institutional Review
Board and registered at ClinicalTrials.gov (NCT02395029).
All participants provided informed consent.
Patients who presented to the clinic with Peyronie disease and who did not want to pursue surgical options at that time were selected for study enrollment. Participants were included in the study if they were aged 18 years or older and had an acquired penile curvature associated with a palpable penile plaque at physical examination and penile plaque at ultrasonography screening.
Patients with any of the following conditions were excluded: current warfarin treatment; inability to Table 1 and Table 2 show the PSV, EDV, and penile measurements in the 5 patients at 6-week and 3-month follow-up, respectively. The 2 patients who refused reinjection of trimix at 3 and 6 months both self-reported an improvement in curvature; patient 1 measured his curvature at 40° at 3 months, and patient 2 reported that his curvature had resolved.
The IIEF scores ranged from 27 to 73 before PM-MSC injection and from 36 to 73 after injection.
This difference was not statistically significant. Stretched penile length and penile girth ( Table 1 and Table 2 ) also did not change statistically significantly. Statistical analysis was performed, with differences considered statistically significant at P<.05. Two-tailed P values were calculated for all measured criteria, including PSV, EDV, stretched penile length, penile girth, and IIEF score. Plaque volumes were presented as raw data, and P values were not calculated for these measurements.
Results
In total, 5 patients aged 45 to 59 years were enrolled in At the beginning of the study, 1 patient had 3 Peyronie plaques, 3 had 2 plaques each, and 1 had a e11 
Conclusion
To our knowledge, this was the first feasibility study on the use of stem cells (PM-MSCs) to manage PD in humans. Although the sample was small, the results were statistically significant and seem promising. They show that PM-MSC treatment may be a future nonsurgical treatment option for patients with PD. The PM-MSC injections also statistically significantly increased PSV.
Further studies of PM-MSC treatment in patients with PD should be conducted to confirm its efficacy.
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